LYEL · Lyell Immunopharma, Inc.

Summary

Lyell Immunopharma, Inc. appointed Smital Shah as Chief Financial and Business Officer and principal financial officer effective March 9, 2026, succeeding Lynn Seely, M.D., who previously served as interim principal financial officer. The appointment includes an annual base salary of $500,000, target bonus up to 50% of base salary, and a stock option for 140,000 shares.

Key takeaways

• Board approved Smital Shah appointment on March 6, 2026, effective March 9, 2026
• Shah receives $500,000 initial annual base salary and target bonus up to $250,000
• Stock option for 140,000 common shares under 2021 Equity Incentive Plan
• 25% vesting after one-year anniversary, then 1/48th monthly thereafter
• Shah participates in Officer Severance Plan as Tier I Employee
• Lynn Seely, M.D. transitions from interim principal financial officer role